Lisby, M, Bonnerup, D K, Brock, B, Gregersen, P A, Jensen, J, Larsen, M-L, Rungby, J, Sonne, J, Mainz, J & Nielsen, L P 2018, ' Medication Review and Patient Outcomes in an Orthopedic Department : A Randomized Controlled Study ', Journal of Patient Safety, vol. 14, no. 2, pp. 74–81 . https://doi.org/10.1097/PTS.0000000000000173 Lisby, M, Bonnerup, D K, Brock, B, Gregersen, P A, Jensen, J, Larsen, M-L, Rungby, J, Sonne, J, Mainz, J & Nielsen, L P 2015, ' Medication Review and Patient Outcomes in an Orthopedic Department : A Randomized Controlled Study ', Journal of Patient Safety . https://doi.org/10.1097/PTS.0000000000000173
Degn, K B, Juhl, C B, Sturis, J, Jakobsen, G, Brock, B, Chandramouli, V, Rungby, J, Landau, B R & Schmitz, O 2004, ' One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α-and β-cell function and reduces endogenous glucose release in patients with Type 2 diabetes ' Diabetes, vol. 53, pp. 1187-1194 .
Mari, A, Degn, K, B., B, J., R, Ferrannini, E & Schmitz, O 2007, ' Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions ', Diabetes Care, vol. 30(8), pp. 2032-3 . Diabetes care 30 (2007): 2032–2033. doi:10.2337/dc07-0310 info:cnr-pdr/source/autori:Mari A.; Degn K.; Brock B.; Rungby J.; Ferrannini E.; Schmitz O./titolo:Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions/doi:10.2337%2Fdc07-0310/rivista:Diabetes care/anno:2007/pagina_da:2032/pagina_a:2033/intervallo_pagine:2032–2033/volume:30